Ontario Teachers Pension Plan Board Has $665,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Ontario Teachers Pension Plan Board trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 31.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,855 shares of the biotechnology company’s stock after selling 839 shares during the period. Ontario Teachers Pension Plan Board’s holdings in United Therapeutics were worth $665,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Comerica Bank boosted its position in shares of United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares in the last quarter. Tri Locum Partners LP bought a new position in United Therapeutics during the second quarter worth about $15,959,000. QRG Capital Management Inc. grew its stake in United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after acquiring an additional 1,692 shares during the period. Canada Pension Plan Investment Board increased its holdings in shares of United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after acquiring an additional 153,700 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on UTHR. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. This represents a 67.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,796 shares of company stock valued at $40,936,370 in the last three months. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 0.8 %

NASDAQ UTHR opened at $367.36 on Friday. The firm’s fifty day moving average price is $364.39 and its two-hundred day moving average price is $330.59. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82. The firm has a market capitalization of $16.40 billion, a P/E ratio of 16.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.38 EPS. On average, research analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.